Lincoln National Corp’s 10x Genomics TXG Stock Holding History

Lincoln National Corp’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-150,205	Closed	-$5.64M	–	1056
2024 Q1	$5.64M	Sell	150,205 -3	-0%	-$132	0.09%	138
2023 Q4	$8.41M	Buy	150,208 +3	+0%	+$131	0.15%	87
2023 Q3	$6.2M	Buy	150,205 +9	+0%	+$468	0.13%	99
2023 Q2	$8.39M	Sell	150,196 -10	-0%	-$541	0.17%	83
2023 Q1	$8.38M	Sell	150,206 -20,000	-12%	-$934K	0.18%	73
2022 Q4	$6.2M	Sell	170,206 -39,917	-19%	-$1.31M	0.14%	91
2022 Q3	$5.98M	Hold	210,123	–	–	0.15%	88
2022 Q2	$9.51M	Hold	210,123	–	–	0.22%	64
2022 Q1	$16M	Sell	210,123 -86	-0%	-$7.52K	0.33%	44
2021 Q4	$31.3M	Buy	+210,209	New	+$32.2M	0.63%	29

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Lincoln National Corp's TXG Position: Q2 2024 in Review

Lincoln National Corp sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 150,205 shares — an estimated $5.64M sold.

Lincoln National Corp first reported a position in TXG in Q4 2021 and held it in 10 quarters. The position peaked at $31.3M in Q4 2021. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

Lincoln National Corp reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
Lincoln National Corp sold 150,205 10x Genomics shares in Q2 2024, an estimated $5.64M.
Lincoln National Corp first reported a position in 10x Genomics in Q4 2021 and held it in 10 quarters.
Lincoln National Corp's 10x Genomics position peaked at $31.3M in Q4 2021.
261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.